7
1
1
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T36091 | LEESGGGLVQPGGSMK acetate | ||
LEESGGGLVQPGGSMK acetate is a proteolysis peptide found in Infliximab, a chimeric monoclonal IgG1 antibody. It serves as a component of Infliximab and can be employed for the quantitative analysis of this antibody. Infli... | |||
T39521 | LEESGGGLVQPGGSMK | ||
LEESGGGLVQPGGSMK, a proteolysis peptide, is a constituent of Infliximab, a chimeric monoclonal IgG1 antibody that selectively binds to TNF-α. It can be employed for quantitative assessment of Infliximab. | |||
T76201 | LEESGGGLVQPGGSMK TFA | ||
LEESGGGLVQPGGSMK TFA, a proteolysis peptide component of Infliximab, serves for the quantitative analysis of the latter. Infliximab is a chimeric monoclonal IgG1 antibody, binding specifically to TNF-α [1]. | |||
T31388L | Desglymidodrine | ||
Desglymidodrine is a Metabolite of midodrine (ST-1085). It is used in plasma of ascitic patients. | |||
T83488 | [Lys8] Vasopressin Desglycinamide | ||
[Lys8] Vasopressin Desglycinamide, a vasopressin analog, supports the maintenance of active and passive avoidance behavior and aids in the facilitation of memory consolidation processes [1]. | |||
T124583 | 26-Desglucoavenacoside A | ||
26-Desglucoavenacoside A is a useful organic compound for research related to life sciences. The catalog number is T124583 and the CAS number is 59795-21-0. | |||
T31388 | Desglymidodrine hydrochloride | ||
Desglymidodrine hydrochloride can be used to treat non azotemic cirrhotic patients with tense ascites. |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TN5304 | Desglucohellebrin | Deglucohellebrin | |
Desglucohellebrin is a natural product for research related to life sciences. The catalog number is TN5304 and the CAS number is 20300-44-1. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02398 | TLE3 Protein, Human, Recombinant (aa 484-772, GST) | Human | E. coli |
The association between high TLE3 expression and a favorable response to taxane-containing chemotherapy regimens was validated in patients with non-serous ovarian cancer. That TLE3 expression may serve as a marker of che... |